Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Alnylam Pharmaceuticals aln
AddedMar 19, 2024
UpdatedJul 9, 2026
Alnylam Pharmaceuticals aln

Alnylam Pharmaceuticals aln

Public

Discovering RNAi therapeutics for genetic diseases. Founded in 2002, headquartered in Cambridge, MA.

HQ
Cambridge, MA, US
Founded
2002
Overview
Compare
Fundraising
Employees
Website

Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is a pioneering biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). The company's mission is to harness RNAi to silence the genes that cause human diseases, offering innovative treatments for genetic conditions, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Alnylam’s marketed products include ONPATTRO (patisiran), a lipid complex injection for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Notable figures affiliated with Alnylam include its co-founder and Nobel laureate Phillip Sharp. The company has attracted significant investment from leading venture capital firms and strategic partners. Key achievements include the successful commercialization of multiple RNAi-based therapies and a robust pipeline addressing a broad range of diseases. Alnylam's impact extends beyond rare diseases, aiming to improve the lives of millions through its groundbreaking RNAi technology.

Alnylam Pharmaceuticals aln - Similar Companies

Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

ionispharma.com

Sirnaomics logo

Sirnaomics

sirnaomics.com

Silence Therapeutics logo

Silence Therapeutics

Atalanta Therapeutics logo

Atalanta Therapeutics

atalantatx.com

Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

amylyx.com

Moderna logo

Moderna

modernatx.com

Alltrna logo

Alltrna

alltrna.com

Phio Pharmaceuticals logo

Phio Pharmaceuticals

phiopharma.com

Quark Pharmaceuticals logo

Quark Pharmaceuticals

Nextrna Therapeutics logo

Nextrna Therapeutics

Traversa Therapeutics logo

Traversa Therapeutics

traversathera.com

Kylin Therapeutics logo

Kylin Therapeutics

Intellia Therapeutics logo

Intellia Therapeutics

intelliatx.com

Regulus Therapeutics logo

Regulus Therapeutics

regulusrx.com

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

Alnylam Pharmaceuticals aln - Quick Facts

Who are Alnylam Pharmaceuticals aln's competitors?

Companies similar to Alnylam Pharmaceuticals aln include Ionis Pharmaceuticals, Sirnaomics, Silence Therapeutics and Atalanta Therapeutics.

When was Alnylam Pharmaceuticals aln founded?

Alnylam Pharmaceuticals aln was founded in 2002.

Where is Alnylam Pharmaceuticals aln's headquarters located?

Alnylam Pharmaceuticals aln's headquarters is located in Cambridge, MA, US.

When was Alnylam Pharmaceuticals aln's last funding round?

Alnylam Pharmaceuticals aln's most recent funding round was for $900M (USD) in September 2022.

How much has Alnylam Pharmaceuticals aln raised to-date?

As of Sep 13, 2022, Alnylam Pharmaceuticals aln has raised a total of $3.9B (USD).

How many employees does Alnylam Pharmaceuticals aln have?

Alnylam Pharmaceuticals aln has 2,002 employees as of Feb 6, 2024.

Alnylam Pharmaceuticals aln - Classification

Ownership
  • Public
Technology
  • Biotech
  • RNAI
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
  • Therapeutics
Tags
  • Healthcare
Unique IDs
  • ein: 770602661
  • secCik: 0001178670
  • ticker: ALNY
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 22 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 621000Ambulatory Health Care Services
  • 621500Medical and Diagnostic Laboratories
  • 621510Medical and Diagnostic Laboratories
  • 621511Medical Laboratories
  • 621512Diagnostic Imaging Centers
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 8070Medical And Dental Laboratories
  • 8071Medical Laboratories
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research
ISIC
  • 8690Other human health activities